Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COL-101 in blepharitis and facial rosacea
NCT00560703Phase 2Completed
- Sponsor
- Galderma
- Start
- Nov 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of doxycycline in blepharitis and rosacea (2 arms), sponsored by Galderma. Primary endpoints: Change in Bulbar Conjunctival Hyperemia at 12 weeks and Change in Ocular Surface Disease Index at 12 weeks. Started Nov 2007; status: completed.
02
Drugs
doxycycline
03
Conditions
blepharitisrosacea
Beyond the preview
Go deeper on NCT00560703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00560703.